Asarfi Hospital Ltd Q1 FY27 Earnings Analysis

- Targeting revenue of INR 260 crores for FY27, up from INR 173.5 crores in FY26. - Aim to scale overall bed capacity to over 500 beds by 2028 (from current 350 beds). - Cancer hospital capacity to increase from 65 beds to 150 beds, with significant revenue growth expected from this segment. - Revenue growth driven by bed expansion, occupancy ramp-up, ARPOB (Average Revenue Per Occupied Bed) improvement, transplant services, and management contracts. - Expect organic and inorganic growth, including hospital acquisitions planned in FY27. - Bone marrow transplant facility to start contributing revenue from FY28. - Long-term plan targets INR 400 crores revenue and EBITDA margin of 23-25%. - PAT growth expected to be aligned with revenue and EBITDA growth, with a focus on cost management and improved case mix. - Confident about sustaining momentum and 50% CAGR growth over next 4-5 years.

- Asarfi Hospital targets revenue growth to INR 260 crores in FY27, with confidence in achieving this through bed expansions, increased patient flow, and service ramp-up. - The company aims to scale bed capacity to over 500 beds by 2028 and generate around INR 400 crores in revenue. - EBITDA margin is expected to improve from 20% in FY26 to 22-25% in FY27, with a focus on case mix optimization and cost management. - PAT margin guidance is 13-15% for FY27, with efforts to maintain PAT growth consistent with revenue growth. - Expansion drivers include cancer hospital growth (increasing from 65 to 150 beds), bone marrow transplant facility commencement (FY28 contribution), and inorganic growth via hospital acquisitions. - Management intends to achieve 50% CAGR growth over the next 4-5 years, maintaining strong profitability and operational discipline. - Internal accruals are expected to fund growth, with limited reliance on debt unless major capex opportunities arise.

- Healthcare Management Research Institute under construction with expected capex of INR 8 to 10 crores in the coming fiscal year. - Additional capex of INR 2 to 3 crores planned to unlock current capacity and expand super specialty and oncology beds — total FY27 capex expected to be under INR 15 crores. - Bed expansion plan to increase cancer hospital beds from 65 to 150, with relatively low capex of INR 2 to 3 crores due to existing infrastructure. - Inorganic growth through hospital acquisition is underway, with technical issues being resolved and materialization expected within the financial year. - Potential strategic management contracts and partnerships in nearby regions are in exploration as part of growth strategy. - Main board migration process initiated after July eligibility. - Future expansions and hospital additions planned, but model still under development considering government cashless scheme constraints.

- Asarfi Hospital Limited has not currently decided to raise debt for further growth. - Growth is planned to be managed through internal accruals as of now. - However, the management remains open to taking debt if a major capital expenditure or opportunity arises. - In the recent call, it was mentioned that if any significant funding need arises, the company will inform stakeholders accordingly. - Regarding equity fundraising, no explicit mention of new equity issuance or fundraising was made during the call. - The company is focused on organic and inorganic growth, including potential acquisitions, which might require funding. - Cash holdings are currently between INR 8 crores to INR 10 crores, which provide some liquidity. - Overall, no immediate plans for fundraising but flexibility to consider debt depending on opportunities.

The transcript provided does not mention any details regarding current or expected order book or pending orders for Asarfi Hospital Limited. The discussion focuses primarily on: - Operational performance, bed capacity expansion - Revenue and EBITDA guidance - Government scheme reimbursements and delays - Capital expenditure plans and acquisitions - Growth outlook and strategic initiatives No specific information on order book or pending orders was disclosed in the Q4 & FY26 earnings conference call transcript.